Literature DB >> 23787903

QT variability during initial exposure to sotalol: experience based on a large electronic medical record.

Peter Weeke1, Jessica Delaney, Jonathan D Mosley, Quinn Wells, Sara Van Driest, Kris Norris, Gayle Kucera, Tanya Stubblefield, Dan M Roden.   

Abstract

AIMS: A prolonged QT interval is associated with increased risk of Torsades de pointes (TdP) and may be fatal. We sought to investigate the extent to which clinical covariates affect the change in QT interval among 'real-world' patients treated with sotalol and followed in an electronic medical record (EMR) system. METHODS AND
RESULTS: We used clinical alerts in our EMR system to identify all patients in whom a new prescription for sotalol was written (2001-11). Rate-corrected QT (QTc) was calculated by Bazett's formula. Correlates of sotalol-induced change in the QTc interval and sotalol discontinuation were examined using linear and logistic regression, respectively. Overall, 541 sotalol-exposed patients were identified (n = 200 women, 37%). The mean first sotalol dose was 86 ± 39 mg, age 64 ± 13 years, and BMI 30 ± 7 kg/m(2). Atrial fibrillation/flutter was the predominant indication (92.2%). After initial exposure, the change in the QTc interval from baseline was highly variable: ΔQTc after 2 h = 3 ± 42 ms (P = 0.17) and 11 ± 37 ms after ≥48 h (P < 0.001). Multivariable linear regression analysis identified female gender and age, reduced left ventricular ejection fraction, high sotalol dose, hypertrophic cardiomyopathy, and loop diuretic co-administration as correlates of increased ΔQTc at ≥48 h (P < 0.05 for all). Within 3 days of initiation, 12% discontinued sotalol of which 31% were because of exaggerated QTc prolongation. One percent developed TdP.
CONCLUSION: In this EMR-based cohort, the increase in QTc with sotalol initiation was highly variable, and multiple clinical factors contributed. These data represent an important step in ongoing work to identify real-world patients likely to tolerate long-term therapy and reinforces the utility of EMR-based cohorts as research tools.

Entities:  

Keywords:  Arrhythmia; Atrial fibrillation; Beta-blocker; Electronic medical records; Long QT syndrome; Torsades de pointes

Mesh:

Substances:

Year:  2013        PMID: 23787903      PMCID: PMC3888125          DOI: 10.1093/europace/eut153

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  22 in total

1.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

Review 2.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

3.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Europace       Date:  2006-09       Impact factor: 5.214

4.  Sex difference in risk of torsade de pointes with d,l-sotalol.

Authors:  M H Lehmann; S Hardy; D Archibald; B quart; D J MacNeil
Journal:  Circulation       Date:  1996-11-15       Impact factor: 29.690

5.  Exaggerated QT prolongation after cardioversion of atrial fibrillation.

Authors:  A M Choy; D Darbar; S Dell'Orto; D M Roden
Journal:  J Am Coll Cardiol       Date:  1999-08       Impact factor: 24.094

6.  Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact.

Authors:  P Gaudron; I Kugler; K Hu; W Bauer; C Eilles; G Ertl
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

7.  Prolongation of the QT interval in heart failure occurs at low but not at high heart rates.

Authors:  P P Davey; C Barlow; G Hart
Journal:  Clin Sci (Lond)       Date:  2000-05       Impact factor: 6.124

8.  Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.

Authors:  C Fiset; B Drolet; B A Hamelin; J Turgeon
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

9.  Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.

Authors:  R F Kehoe; T A Zheutlin; C S Dunnington; T A Mattioni; G Yu; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

10.  Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.

Authors:  M K Chung; R A Schweikert; B L Wilkoff; M J Niebauer; S L Pinski; R G Trohman; G A Kidwell; F J Jaeger; V A Morant; D P Miller; P J Tchou
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

View more
  6 in total

1.  Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.

Authors:  Peter Weeke; Jonathan D Mosley; David Hanna; Jessica T Delaney; Christian Shaffer; Quinn S Wells; Sara Van Driest; Jason H Karnes; Christie Ingram; Yan Guo; Yu Shyr; Kris Norris; Prince J Kannankeril; Andrea H Ramirez; Joshua D Smith; Elaine R Mardis; Deborah Nickerson; Alfred L George; Dan M Roden
Journal:  J Am Coll Cardiol       Date:  2014-02-19       Impact factor: 24.094

2.  QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology.

Authors:  Mathias Baumert; Alberto Porta; Marc A Vos; Marek Malik; Jean-Philippe Couderc; Pablo Laguna; Gianfranco Piccirillo; Godfrey L Smith; Larisa G Tereshchenko; Paul G A Volders
Journal:  Europace       Date:  2016-01-27       Impact factor: 5.214

3.  Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.

Authors:  Hanna Lenhoff; Börje Darpö; Alex Page; Jean Philippe Couderc; Per Tornvall; Mats Frick
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-02-25       Impact factor: 1.468

4.  GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOL study": Lack of common variants with large effect sizes.

Authors:  Joe-Elie Salem; Marine Germain; Jean-Sébastien Hulot; Pascal Voiriot; Bruno Lebourgeois; Jean Waldura; David-Alexandre Tregouet; Beny Charbit; Christian Funck-Brentano
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

Review 5.  Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes.

Authors:  Stacy Westerman; Nanette Wenger
Journal:  Curr Cardiol Rev       Date:  2019

Review 6.  Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.

Authors:  Paz Ovics; Danielle Regev; Polina Baskin; Mor Davidor; Yuval Shemer; Shunit Neeman; Yael Ben-Haim; Ofer Binah
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.